Literature DB >> 15050911

Endostatin's endpoints-Deciphering the endostatin antiangiogenic pathway.

Robert Benezra1, Shahin Rafii.   

Abstract

Up until now, the precise mechanism for endostatin's antiangiogenesis action was not known. In a recent report, have taken advantage of gene array and proteomic analysis to map the antiangiogenic pathways turned on by endostatin. This study resolves some of the controversies surrounding endostatin's biology, and provides a new direction to help dissect the molecular pathways involved in endostatin's selective tumor antiangiogenic effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15050911     DOI: 10.1016/s1535-6108(04)00057-1

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  6 in total

1.  A hypoxia-responsive glial cell-specific gene therapy vector for targeting retinal neovascularization.

Authors:  Manas R Biswal; Howard M Prentice; C Kathleen Dorey; Janet C Blanks
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-11-06       Impact factor: 4.799

2.  The anti-angiogenic peptide anginex disrupts the cell membrane.

Authors:  Jan Pilch; Carla M Franzin; Lynn M Knowles; Fernando J Ferrer; Francesca M Marassi; Erkki Ruoslahti
Journal:  J Mol Biol       Date:  2005-12-20       Impact factor: 5.469

3.  Lack of endothelial cell survivin causes embryonic defects in angiogenesis, cardiogenesis, and neural tube closure.

Authors:  Femke Zwerts; Florea Lupu; Astrid De Vriese; Saskia Pollefeyt; Lieve Moons; Rachel A Altura; Yuying Jiang; Patrick H Maxwell; Peter Hill; Hideyasu Oh; Claus Rieker; Désiré Collen; Simon J Conway; Edward M Conway
Journal:  Blood       Date:  2007-02-13       Impact factor: 22.113

Review 4.  Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis.

Authors:  Gustav J Strijkers; Ewelina Kluza; Geralda A F Van Tilborg; Daisy W J van der Schaft; Arjan W Griffioen; Willem J M Mulder; Klaas Nicolay
Journal:  Angiogenesis       Date:  2010-06       Impact factor: 9.596

5.  Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study.

Authors:  Jianghao Chen; Qing Yao; Dong Li; Juliang Zhang; Ting Wang; Ming Yu; Xiaodong Zhou; Yi Huan; Jing Wang; Ling Wang
Journal:  BMC Cancer       Date:  2013-05-21       Impact factor: 4.430

6.  Endostatin/collagen XVIII is increased in cerebrospinal fluid after severe traumatic brain injury.

Authors:  Hao Chen; Li-Xia Xue; He-Li Cao; Shi-Wen Chen; Yan Guo; Wen-Wei Gao; Shi-Ming Ju; Heng-Li Tian
Journal:  Biomed Res Int       Date:  2013-09-08       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.